SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of proprietary antibody therapeutics. Its platform includes common light chain-focused antibody discovery, human display for antibody tuning, stitchmabs, and highly modular and manufacturable bispecific candidates. The company was founded by Thomas J. Schuetz in 2014 and is headquartered in Boston, MA.

Compass Therapeutics Inc

Compass Therapeutics is trending following a trading halt prompted by the news that its drug tovecimig did not meet the overall survival secondary endpoint in a Phase 2/3 study. The community is actively debating the implications for the company's regulatory path and future BLA filing, with significant skepticism regarding the trial design and statistical outcomes.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

DRTS is gaining significant momentum as investors anticipate major catalysts, including an upcoming oral presentation of pancreatic cancer data at Digestive Disease Week and multiple ongoing clinical trial milestones. The community is actively discussing the company's progress in targeting difficult-to-treat solid tumors, with many viewing the current valuation as an accumulation opportunity ahead of potential data readouts.

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

Intellia Therapeutics is trending following the release of positive pivotal trial data for its in vivo CRISPR-based hereditary angioedema treatment, which has sparked significant debate regarding its commercial potential compared to existing therapies. While the community is actively discussing the validation of the company's gene-editing platform, the stock's price action remains volatile as investors weigh the breakthrough clinical results against concerns about market competition and future reimbursement.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

Greenland Energy Co. is a blank check company. It was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was founded on July 23, 2024 and is headquartered in New York, NY.

Greenland Energy Co.

Greenland Energy (GLND) is surging as community sentiment centers on a major drilling partnership with Halliburton for a 2026 campaign in the Jameson Land Basin, which investors view as a pivotal validation of the company's Arctic oil and mineral assets. Discussions are heavily focused on the stock's low float, extreme short interest, and the potential for a significant squeeze amid heightened global interest in energy security.

Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.

Oruka Therapeutics Inc.

Oruka Therapeutics is trending following positive interim Phase 2a results for ORKA-001 in psoriasis, which hit its primary endpoint and showed potential for annual dosing. The community is actively debating the company's long-term valuation compared to sector peers and monitoring potential dilution as the firm moves toward larger late-stage trials.

Sagimet Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics for the treatment of infectious diseases. Its lead drug candidate, denifanstat, is an oral, once-daily pill and selective fatty acid synthase (FASN) inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH). The company was founded by Urs F. Greber, Ari Helenius, and Lucas Pelkmans on December 19, 2006 and is headquartered in San Mateo, CA.

Sagimet Biosciences Inc - Ordinary Shares - Series A

Sagimet Biosciences Inc

Sagimet Biosciences (SGMT) is trending as the market processes the company's strategic decision to prioritize its acne program, including the upcoming initiation of a Phase 3 trial, alongside a successful capital raise of $175 million. The community is actively debating the impact of this significant equity offering on dilution versus the potential validation of the company's long-term commercial runway and accelerated development timeline for denifanstat.

Velo3D, Inc. operates as a technology company, which engages in developing and manufacturing metal laser sintering printing machines for 3D printing. Its products include assure system, flow software, sapphire printer & sapphire XC. The company was founded by Benyamin Buller in June 2014 and is headquartered in Fremont, CA.

Velo3D Inc

QUALCOMM, Inc. engages in developing and commercializing foundational technologies and products used in mobile devices and other wireless products. It operates through the following segments: Qualcomm CDMA Technologies (QCT), Qualcomm Technology Licensing (QTL), and Qualcomm Strategic Initiatives (QSI). The QCT segment develops and supplies integrated circuits and system software based on technologies for use in voice and data communications, networking, application processing, multimedia, and global positioning system products. The QTL segment grants licenses and provides rights to use portions of the firm's intellectual property portfolio. The QSI segment focuses on opening new or expanding opportunities for its technologies and supporting the design and introduction of new products and services for voice and data communications. The company was founded by Franklin P. Antonio, Adelia A. Coffman, Andrew Cohen, Klein Gilhousen, Irwin Mark Jacobs, Andrew J. Viterbi, and Harvey P. White in July 1985 and is headquartered in San Diego, CA.

Qualcomm, Inc.

Qualcomm is trending as investors react to a significant revenue outlook miss for the upcoming quarter and broader memory supply constraints that are pressuring smartphone handset sales. Community sentiment is deeply divided, with many debating the impact of these headwinds versus the potential for long-term growth through AI-powered smartphone chips, upcoming automotive design wins, and aggressive stock buyback programs.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

CorMedix is under intense focus as investors weigh the company's Q4 financial performance against a conservative 2026 outlook and the upcoming TDAPA reimbursement transition. The community is actively debating the company's commercial execution and the potential for a rebound driven by a share buyback program and upcoming Phase 3 trial data.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

First Community Bancshares (NASDAQ:FCBC) Stock Price Passes Above Two Hundred Day Moving Average   - Time to Sell?

First Community Bancshares (NASDAQ:FCBC) Stock Passes Above Two Hundred Day Moving Average - Should You Sell...

First Community Bancshares, Inc. (NASDAQ:FCBC) Short Interest Up 19.6% in March

First Community Bancshares, Inc. (NASDAQ:FCBC - Get Free Report) was the recipient of a significant growth in short interest during the month of March. As of March 31st, there was short interest...

First Community Bancshares (NASDAQ:FCBC) Hits New 52-Week High - What's Next?

First Community Bancshares (NASDAQ:FCBC) Sets New 1-Year High - What's Next...

First Community Bancshares (FCBC) Expected to Announce Quarterly Earnings on Tuesday

First Community Bancshares (NASDAQ:FCBC) will be releasing its Q1 2026 earnings before the market opens on Tuesday, April 21. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-4-21-first-community-bankshares-inc-stock...

First Community Bancshares (NASDAQ:FCBC) Reaches New 52-Week High  - Here's What Happened

First Community Bancshares (NASDAQ:FCBC) Sets New 1-Year High - Here's Why...

First Community Bancshares (NASDAQ:FCBC) Stock Passes Above 200-Day Moving Average - Here's What Happened

First Community Bancshares (NASDAQ:FCBC) Share Price Crosses Above 200-Day Moving Average - Here's What Happened...

First Community Bancshares (NASDAQ:FCBC) Hits New 1-Year High - What's Next?

First Community Bancshares (NASDAQ:FCBC) Sets New 52-Week High - Still a Buy...

First Community Bancshares, Inc. (NASDAQ:FCBC) Short Interest Update

First Community Bancshares, Inc. (NASDAQ:FCBC - Get Free Report) was the target of a significant increase in short interest during the month of March. As of March 13th, there was short interest...

First Community Bancshares (NASDAQ:FCBC) Share Price Passes Above Two Hundred Day Moving Average - Here's Why

First Community Bancshares (NASDAQ:FCBC) Stock Crosses Above Two Hundred Day Moving Average - Time to Sell...

Short Interest in First Community Bancshares, Inc. (NASDAQ:FCBC) Grows By 37.4%

First Community Bancshares, Inc. (NASDAQ:FCBC - Get Free Report) saw a large increase in short interest in February. As of February 13th, there was short interest totaling 235,146 shares, an increase...

First Community Bancshares, Inc. operates as a financial holding company, which engages in the provision of banking products and services to individual and commercial customers. The firm offers demand deposit accounts, savings and money market accounts, certificates of deposit, individual retirement arrangements, commercial, consumer, and real estate mortgage loans, lines of credit, various credit card, debit card, automated teller machine card services, corporate and personal trust services, investment management services, and life, health, and property and casualty insurance products. It offers its services and products to individuals and businesses that includes industries such as education, government, health services, retail trade, construction, manufacturing, tourism, coal mining and gas extraction, and transportation. The company was founded in 1989 and is headquartered in Bluefield, VA.

Fiscal Period	Estimated	Reported	Surprise	Result
Q1 '26	$0.72	--	--	N/A
Q4 '25	$0.62	$0.77	24.19%	BEAT
Q3 '25	$0.63	$0.70	11.11%	BEAT
Q2 '25	$0.65	$0.67	3.08%	BEAT
Q1 '25	$0.64	$0.64	--	EXPECTED

FCBC
First Community Bankshares Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q1 '26

Historical Earnings

Latest FCBC News

FCBCFirst Community Bankshares Inc.